Cargando…

Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()

Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Komnitski, Melpone, Komnitski, Angelo, Komnitski Junior, Amilton, Silva de Castro, Caio César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335860/
https://www.ncbi.nlm.nih.gov/pubmed/32418716
http://dx.doi.org/10.1016/j.abd.2019.08.032
_version_ 1783554205826416640
author Komnitski, Melpone
Komnitski, Angelo
Komnitski Junior, Amilton
Silva de Castro, Caio César
author_facet Komnitski, Melpone
Komnitski, Angelo
Komnitski Junior, Amilton
Silva de Castro, Caio César
author_sort Komnitski, Melpone
collection PubMed
description Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.
format Online
Article
Text
id pubmed-7335860
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-73358602020-07-07 Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()() Komnitski, Melpone Komnitski, Angelo Komnitski Junior, Amilton Silva de Castro, Caio César An Bras Dermatol Case Report Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment. Sociedade Brasileira de Dermatologia 2020 2020-05-05 /pmc/articles/PMC7335860/ /pubmed/32418716 http://dx.doi.org/10.1016/j.abd.2019.08.032 Text en © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Komnitski, Melpone
Komnitski, Angelo
Komnitski Junior, Amilton
Silva de Castro, Caio César
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title_full Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title_fullStr Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title_full_unstemmed Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title_short Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
title_sort partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335860/
https://www.ncbi.nlm.nih.gov/pubmed/32418716
http://dx.doi.org/10.1016/j.abd.2019.08.032
work_keys_str_mv AT komnitskimelpone partialrepigmentationofvitiligowithtofacitinibwithoutexposuretoultravioletradiation
AT komnitskiangelo partialrepigmentationofvitiligowithtofacitinibwithoutexposuretoultravioletradiation
AT komnitskijunioramilton partialrepigmentationofvitiligowithtofacitinibwithoutexposuretoultravioletradiation
AT silvadecastrocaiocesar partialrepigmentationofvitiligowithtofacitinibwithoutexposuretoultravioletradiation